Merck reduced its acquisition offer for Terns Pharmaceuticals from $61 to $53 per share after reviewing updated clinical trial data for TERN-701, showing a lower MMR achievement rate than expected. A competing bidder also withdrew its offer due to concerns about the drug's differentiation and risk profile, though Merck maintained enthusiasm for the deal.

Merck & Co. shares declined 3.12% on Tuesday amid a broader market downturn, with the S&P 500 down 0.9% and the Healthcare sector down 0.5%. The decline occurred despite positive momentum from Merck's announced acquisition of Terns Pharmaceuticals for $53.00 per share in cash. While technical indicators show bullish signals with strong 12-month gains of 44.67%, the stock faces intermediate-term weakness and sector headwinds.

Merck announced its acquisition of Terns Pharmaceutical for $6.7 billion to bolster its cancer treatment pipeline with TERN-701, an oral BCR-ABL1 inhibitor for chronic myeloid leukemia. This marks the third multi-billion-dollar acquisition in a year, reinforcing Merck's M&A strategy. The company has a strong earnings track record, forecasts over $70 billion in commercial opportunity by mid-2030s, maintains a 73% gross margin, and has increased dividends for 14 consecutive years.

Merck & Co entered a collaboration with Infinimmune to develop next-generation antibody drugs using Infinimmune's human-first discovery platform and machine learning technology. Under the deal, Merck gains exclusive development and commercial rights to antibody candidates, with Infinimmune eligible to receive up to $838 million in milestone payments. Merck shares were up 0.34% in premarket trading, approaching their 52-week high.

Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion ($53 per share) to bolster its pipeline ahead of Keytruda's patent expiry in 2028. The deal focuses on Terns' early-stage CML treatment TERN-701. However, analysts suggest the offer may undervalue the asset and could attract competing bids from other pharmaceutical companies.

Merck announced it will acquire clinical-stage oncology company Terns Pharmaceuticals for $53.00 per share in cash, representing an approximate equity value of $6.7 billion. The acquisition focuses on TERN-701, a novel oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for chronic myeloid leukemia (CML). The deal represents a 31% premium to the 60-day volume-weighted average stock price and is expected to close in Q2 2026.

Merck is nearing a $6 billion all-cash acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiration. Terns is developing an early-stage CML treatment that could compete with Novartis's Scemblix. The deal reflects Merck's broader strategy to secure future growth as the pharmaceutical industry faces $320 billion in revenue losses from patent expirations through 2030.

Vestal Point Capital sold 1.054 million shares of Nuvalent (NUVL) for approximately $103.93 million in Q4, reducing its position to less than 1% of assets under management. Despite the sale, Nuvalent shares have rallied nearly 30% over the past year and the company is well-positioned financially with $1.4 billion in cash, awaiting potential FDA decisions on its cancer drug candidates later in 2026.

ORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data to determine if the valuation is justified.

First Turn Management disclosed a $35.23 million position in clinical-stage biotech Terns Pharmaceuticals (872,049 shares), representing 4.03% of the fund's assets. The investment comes as TERN stock has surged 826% over the past year, driven by strong Phase 1 data for TERN-701 in cancer treatment. The article cautions investors to separate momentum from fundamentals, noting that clinical-stage biotech carries significant volatility and valuation risk despite compelling science.

Terns Pharmaceuticals plans to raise $650 million through a public offering of 16,250,000 shares at $40.00 per share, with proceeds intended to fund research, clinical trials, and development of product candidates like TERN-701.

Terns Pharmaceuticals reported promising Phase 1 clinical trial results for TERN-701, an investigational BCR::ABL1 inhibitor for chronic myeloid leukemia (CML), showing 64-75% major molecular response rates and a favorable safety profile across patient subgroups.